X

Due to the lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at http://www.usa.gov.
NIH Guide: FINDINGS OF SCIENTIFIC MISCONDUCT

FINDINGS OF SCIENTIFIC MISCONDUCT

NIH GUIDE, Volume 24, Number 18, May 19, 1995



P.T. 34



Keywords:

  Ethics/Values in Science & Technol 

  Grants Administration/Policy+ 



Department of Health and Human Services



Notice is hereby given that the Office of Research Integrity (ORI)

has made final findings of scientific misconduct in the following

cases:



Denise R. Conrad, University of Iowa:  The Division of Research

Investigations (DRI) of the Office of Research Integrity (ORI)

reviewed an investigation conducted by the University of Iowa into

possible scientific misconduct on the part of Ms. Denise R. Conrad,

formerly a Research Assistant in the Department of Preventive

Medicine, College of Medicine.  ORI found that Ms. Conrad committed

scientific misconduct by fabricating or falsifying data on

questionnaires in biomedical research supported by Public Health

Service grant R01 ES05653, "Residential Radon and Lung Cancer Case-

Control Study." Ms. Conrad has accepted the ORI findings and agreed

to a Voluntary Exclusion Agreement under which Ms. Conrad is not

eligible to apply for or receive any Federal grant or contract funds

for a three-year period beginning April 10, 1995.  The fabricated or

falsified data did not appear in any publication.



Catherine Coyle, ISOLAB, Inc.:  An investigation conducted by the

ISOLAB found that Ms. Coyle, a former laboratory technician,

falsified and misreported the results of assays for fetal hemoglobin

data generated for Johns Hopkins' Multicenter Study of Hydroxyurea in

Sickle Cell Anemia in biomedical research supported by Public Health

Service funds under a cooperative agreement.  Ms. Coyle admitted that

she misrepresented data submitted to the Johns Hopkins clinical

hydroxyurea study.  There were no publications involved.  Ms. Coyle

executed a Voluntary Exclusion and Settlement Agreement in which she

has agreed not to apply for Federal grant or contract funds and will

not serve on PHS advisory committees, boards or peer review groups

for a three-year period beginning March 27, 1995.



Terence S. Herman, M.D., Harvard Medical School:  The Division of

Research Investigations (DRI) of the Office of Research Integrity

(ORI) reviewed an investigation conducted by Harvard Medical School

into possible scientific misconduct on the part of Dr. Herman while

he was an employee of that institution.  ORI concurred with the

factual findings as set forth in the institution's report, and finds

that Dr. Herman committed scientific misconduct by falsely reporting

in a published article that research had been conducted according to

a stated protocol when, in fact, Dr. Herman knew at the time that the

protocol for tumor measurements had not been carried out exactly as

described.  The research was supported by grant awards from the

National Cancer Institute and the National Center for Research

Resources, National Institutes of Health.



Dr. Herman accepted the misconduct finding as part of a Voluntary

Settlement Agreement under which, for a period of three years, any

institution which submits an application for PHS support for a

clinical research project on which his participation is proposed or

which uses him in any capacity on PHS supported clinical research

must concurrently submit a plan for supervision of his duties.  The

supervisory plan must be designed to ensure the scientific integrity

of Dr. Herman's research contribution.  Dr. Herman also is prohibited

from serving on any Public Health Service advisory committee, board,

and/or peer review committee for a period of three years.  He has

agreed to submit a letter to the International Journal of Radiation

Oncology, Biology, Physics requesting retraction of that portion of

the article dealing with tumor response (Herman, et al., A Phase I-II

Trial of Cisplatin, Hyperthermia and Radiation in patients with

Locally Advanced Malignancies. Int. J. Radiation Oncology Biol. Phys.

17:1273-1278; 1989).



INQUIRIES



For further information, contact:



Director

Division of Research Investigations

Office of Research Integrity

5515 Security Lane, Suite 700

Rockville, MD  20852

Telephone:  (301) 443-5330



.


Return to 1995 Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.